Drugs / INCB177054
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06873789 | Jun 2025 → Jul 2026 | cancer, metastatic neoplasm | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-25 | Incyte Corporation | Results Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 incyte.com ↗
INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-25 | Incyte Corporation | Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 incyte.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB177054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06873789 ↗ |